You are here

Share:

Search Technologies

Showing 1-20 of 164 results found

Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome

Scientists at the National Cancer Institute (NCI) have developed SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a computational precision-oncology framework harnessing genetic interactions to improve treatment options for cancer patients. NCI seeks collaborators or licensees to advance the development of this technology into precision diagnostics.

CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles

Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).

Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection

Investigators at the National Cancer Institute (NCI) have discovered an adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is composed of a novel molecular adjuvant nanoparticle that induces robust humoral and cellular immunity, as well as trained innate immunity with enhanced protection against respiratory SARS-CoV-2 exposure. The technology is available for potential licensing or collaborative research to co-develop these therapeutic targets.

Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression

Researchers at the National Cancer Institute (NCI) have developed a bioluminescent MB49-luciferase bladder cancer cell line that can be used in preclinical studies to evaluate anti-cancer agents in bladder cancer. NCI seeks parties to non-exclusively license this research material.

Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs

Researchers at the National Cancer Institute (NCI) seek licensing and/or co-development research collaborations for peptide-based virus-like nanoparticles that are fully synthetic and capable of delivering cytotoxic, radioactive, and imaging agents. The researchers are interested in commercial partners to conduct pre-clinical and pre-IND studies.

Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)

Adoptive cell therapy (ACT) using tumor-specific T cells leads to complete tumor regression in some cancer patients. However, limiting the efficacy of this therapy is that T cells become functionally exhausted and have short half-lives after adoptive transfer. Researchers at the National Cancer Institute (NCI) have discovered a novel method to generate long-lived memory tumor-specific T cells with enhanced tumor clearance and persistence upon in vivo transfer. NCI is seeking parties interested in licensing and/or co-developing potassium hydroxy citrate to promote longevity and efficacy of tumor-specific T cells.

Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1

Researchers at the National Cancer Institute (NCI) have developed a combination of immunoadjuvants and immune checkpoint inhibitors to stimulate an immune response against cancer. The combination therapy has been tested in xenograft models and shown successful for both treatment of an existing tumor and resistance to re-challenge. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.

Anti-SLAMF7 Chimeric Antigen Receptors

Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target Signaling Lymphocyte Activation Molecule F7 (SLAMF7) are strong therapeutic candidates for patients with Multiple Myeloma (MM). SLAMF7 is highly expressed on the malignant plasma cells that constitute MM. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 an attractive therapeutic target for MM. Researchers at the National Cancer Institute (NCI) have invented anti- SLAMF7 CAR constructs that allow genetically-modified T cells to express both the anti-SLAMF7 antibody and a suicide gene that allows T cells to specifically recognize and kill SLAMF7-expressing cells as well as allow for on-demand and reliable elimination of anti-SLAMF7 CAR T cells. NCI seeks licensing and/or co-development partners for this invention.

Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine

To date, there is no FDA-approved therapeutic vaccine for human papillomavirus (HPV). Researchers at the National Cancer Institute (NCI) have discovered agonist epitopes for the development of an HPV therapeutic vaccine. NCI is seeking parties interested in licensing and/or co-developing HPV agonist epitopes that enhance the activation of cytotoxic T lymphocytes (CTL) and lysis of human tumor cells.

The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof

Researchers at the National Cancer Institute (NCI) have developed an invention describing the binding domain (G2BD) for the ubiquitin-conjugating enzyme Ube2G2 in the gp78 ubiqutin ligase protein. The invention involves modulating the interaction between the gp78 protein and the conjugating enzyme Ube2G2. Interruption of this interaction will block degradation from the endoplasmic reticulum (ER), resulting in ER stress, unfolded protein response, and, ultimately, apoptosis in some cancer cells. The NCI seeks licensing and/or co-development partners for this invention.

T cell Receptors Which Recognize Mutated EGFR

Researchers at the National Cancer Institute (NCI) have isolated T cell receptors (TCRs) that target specific mutations in the epidermal growth factor receptor (EGFR). The mutated protein recognized by these TCRs is frequently expressed in non-small cell lung cancer (NSCLC). These TCRs can be used for a variety of therapeutic applications, including engineered adoptive cell immunotherapy. Researchers at the NCI seek licensing and/or co-development research collaborations for these novel T cell receptors that recognize EGFR mutations.

Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy

Researchers at the National Cancer Institute (NCI) have developed a method to improve the function of therapeutic engineered T cells used for Adoptive T Cell Therapy (ACT) for various cancers and diseases through the co-expression of Interleukin-15 (IL-15) and IL-21 by a flexible linker to the cell membrane. Researchers at the NCI seek licensing for this invention.

Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer

Researchers at the National Cancer Institute (NCI) have discovered that primary bile acids and antibiotics are a novel therapeutic for the treatment of liver cancer and liver metastases. NCI is seeking parties interested in licensing and/or co-developing primary bile acids and antibiotics that have been demonstrated in vivo to attract natural killer T (NKT) cells to the liver and inhibit tumor development.

Methods For Treating or Preventing Inflammation and Periodontitis

Natural products have long been considered a source of biologically active molecules against health disorders, including bone-loss related diseases. Cinnamolyoxy-mammeisin (CNM), can be isolated from Brazilian geopropolis and demonstrates anti-inflammatory activity. Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the Piracicaba Dental School, University of Campinas, Brazil, have shown CNM also demonstrates inhibition of oral bone loss. This invention is available for licensing and/or co-development opportunities.

Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use

Researchers at the National Cancer Institute (NCI) developed several high-affinity monoclonal antibodies to treat Fibroblast Growth Factor Receptor 4 (FGFR4)-related diseases including rhabdomyosarcoma and cancers of the liver, lung, pancreas, ovary and prostate. These antibodies have been used to generate antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), which are capable of specifically targeting and killing diseased cells. NCI seeks co-development opportunities or licensees for this technology.

Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies

Researchers at the National Cancer Institute (NCI) seek research & co-development and/or licensees for a novel, ex vivo method by which stem cell-like memory T cells (Tscm) can be generated by stimulating naïve T cells in the presence of inhibitors of GSK-3beta, which are capable of activating the Wnt pathway. These Tscm cells, generated using GSK-3beta inhibitors, display enhanced survival and proliferation upon transfer, have multipotent capacity to generate all memory and effector T cell subsets, and show increased anti-tumor activity in a humanized mouse tumor model.

New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies

Researchers at the National Cancer Institute (NCI) have developed a new format for expressing Chimeric Antigen Receptors (CARs) that is available for licensing and co-development. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. The novel technology is useful for improving CAR therapies to treat a range of cancers.

Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Researchers at the National Cancer Institute (NCI) seek research co-development or licenses for a method of stimulating an immune response in a human at risk for infection by, or already infected with, an HIV-1 retrovirus. This method utilizes DNA vaccines to stimulate CD8+ T cell immune responses.

Improved HIV Vaccines Through Ras Activation

The National Cancer Institute (NCI) Vaccine Branch, seeks research co-development or licenses for a novel method of improving HIV vaccine efficacy by activating Ras signaling. Upregulating the Ras pathway can improve an HIV patient’s immune response to anti-retroviral vaccines.

Pages